These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3625263)

  • 21. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The use of state of the art statistical methodology in biomedical research: the example of methodology for interim analyses in clinical trials].
    Muñoz SR; Bangdiwala SI
    Rev Med Chil; 2001 Sep; 129(9):983-8. PubMed ID: 11725478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Policies for interim analysis and interim reporting of results.
    O'Fallon JR
    Cancer Treat Rep; 1985 Oct; 69(10):1101-6. PubMed ID: 4042090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive clinical trial design.
    Chow SC
    Annu Rev Med; 2014; 65():405-15. PubMed ID: 24422576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p-value and power computations in multiple look trials.
    Peace KE; Schriver RC
    J Chronic Dis; 1987; 40(1):23-30. PubMed ID: 3805230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [When is enough evidence available?; interim analyses in clinical trials].
    van der Tweel Iv; Roes KC
    Ned Tijdschr Geneeskd; 2013; 157(12):A5660. PubMed ID: 23515039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overestimation of the effect size in group sequential trials.
    Zhang JJ; Blumenthal GM; He K; Tang S; Cortazar P; Sridhara R
    Clin Cancer Res; 2012 Sep; 18(18):4872-6. PubMed ID: 22753584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategy and alternate randomized designs in cancer clinical trials.
    Zelen M
    Cancer Treat Rep; 1982 May; 66(5):1095-100. PubMed ID: 7083213
    [No Abstract]   [Full Text] [Related]  

  • 33. Meta-analyses of randomized controlled trials.
    Sacks HS; Berrier J; Reitman D; Ancona-Berk VA; Chalmers TC
    N Engl J Med; 1987 Feb; 316(8):450-5. PubMed ID: 3807986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An efficient design for phase III studies of combination chemotherapies.
    Ellenberg SS; Eisenberger MA
    Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093
    [No Abstract]   [Full Text] [Related]  

  • 35. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and analysis of controlled clinical trials in rheumatic diseases.
    Williams HJ; Reading JC; Ward JR
    Clin Rheum Dis; 1983 Dec; 9(3):499-514. PubMed ID: 6606530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact that group sequential tests would have made on ECOG clinical trials.
    Rosner GL; Tsiatis AA
    Stat Med; 1989 Apr; 8(4):505-16. PubMed ID: 2657957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials in cancer research.
    Gehan EA
    Environ Health Perspect; 1979 Oct; 32():31-48. PubMed ID: 232043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.